Apollomics (APLM) via Maxpro Capital (JMAC) deck
Apollomics is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.
This post is for subscribers onlySubscribe
Already have an account? Log in